TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting (“ISCT 2025”), a major global cell and gene therapy translation conference, taking place from May 7-10, 2025 in New Orleans, Louisiana, United States.
As part of the Company’s growth and awareness strategy for its expansion into the United States, NurExone will be highlighting its innovative ExoPTEN therapy in a presentation during ISCT 2025 titled: “ExoPTEN: Allogeneic Exosome Therapy for Spinal Cord Injury with Strong Therapeutic Potential and Clinical Promise.” The presentation will cover the Company’s robust preclinical data, demonstrating that a minimally invasive ExoPTEN treatment cycle significantly improved motor and sensory functions and structural recovery in small animal models of spinal cord injury.
“We are honored to present this cutting-edge research to leading experts in the field and further establish our position as a pioneer in exosome-based regenerative therapies,” said Dr. Tali Kizhner, Director of Research and Development at NurExone. “Participating in high-profile U.S. conferences such as ISCT 2025 is central to our strategy of increasing NurExone’s visibility within the North American biotech and investor communities.”